Conclusion of license agreement for IBUDILAST with MEDICINOVA
October 25, 2004
KYORIN Pharmaceutical Co., Ltd. (President: Ikuo Ogihara) announces that it has concluded the License Agreement with MediciNova, Inc., a U.S. corporation (President & CEO: Takashi Kiyoizumi, M.D., Ph.D.) for Ibudilast (Brand Name: Ketas® Capsule) which KOYRIN originated for bronchial asthma and cerebrovascular disorders under the following principal terms
Adobe Reader software is required to view and print PDF files. The latest version of Adobe Reader can be downloaded by accessing the Adobe Systems Incorporated website.